“We are pleased to share that we have continued the strong business momentum with recording robust revenue along with profitability during Q2FY22. This strong performance has been on the back of growth in sustainable non-covid revenue, increased patient visits & tests and increased contribution from specialized tests. With economy now strongly recovering from the pandemic, we expect our non-covid business to continue grow sustainably. Our recently acquired Hitech Diagnostics will further enable us to scale up our business, improve the B2C revenue contribution and increase our market penetration by catering to the value segment of the market.” – Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.
Key highlights of the results
- Patient visits increased by 25% on YoY basis to 3.3 Mn.
- No. of tests increased by 29% on YoY basis to 6.2 Mn.
- Non-Covid Home Visits Revenue increased by 17% on YoY basis to Rs. 26 Crs.
- Revenue contribution from specialised tests (non-covid) increased to 43% in Q2FY22 from 39% in Q2FY21
|In INR Crs.||Q2FY22||Q2FY21|
|Revenue from Operations||302.6||288.4|
|EBITDA before CSR & ESOP||93.2||94.9|
|Reported Profit After Tax||58.4||60.5|
|Reported PAT Margin (%)||19.3%||21.0%|
For report please click here.